Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Denmark
Clinical trial register · European Union · CTIS

Clinical Trials in Denmark, 2026

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2554 most recently authorised of 12905 total CTIS records — a stated recency window, not the full historical archive. Synced 21 Nov 2026, 03:17 UTC
2554
Shown in this register
most recently authorised
12,905
Total on CTIS
full historical archive
780
Phase III
within the shown window
Top member states
Spain 1064 France 921 Germany 904 Italy 766 Poland 624 Netherlands 546

Trials with a site in Denmark

311 of 2554 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase III
Rapport Therapeutics Inc.
Nervous System Diseases
Denmark, Czechia, Lithuania, Hungary, Portugal, Poland, Ireland, Greece, Germany, Slovakia, Spain, Finland, Netherlands, Sweden
18/11/2026
Phase III
Theranexus
Nervous System Diseases
Denmark, Italy, Germany, France, Netherlands, Sweden
16/11/2026
Phase III
Calcilytix Therapeutics Inc.
Hormonal diseases
France, Italy, Spain, Czechia, Netherlands, Denmark, Germany, Hungary, Poland
16/11/2026
Phase III
Rapport Therapeutics Inc.
Nervous System Diseases
Netherlands, Austria, Czechia, Belgium, Slovakia, Finland, Poland, Spain, Ireland, Sweden, Germany, Hungary, Denmark, Italy, Portugal
11/11/2026
Phase III
F. Hoffmann-La Roche AG
Nutritional and Metabolic Diseases
Hungary, Ireland, Germany, Spain, Romania, Denmark, Poland, France, Italy
09/11/2026
Phase II
Aarhus Universitet
Diagnosis
Denmark
09/11/2026
Phase I
Eli Lilly & Co.
Neoplasms
Italy, France, Denmark, Poland, Spain, Germany
02/11/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Nervous System Diseases
Hungary, Belgium, Lithuania, Spain, France, Germany, Netherlands, Poland, Denmark, Slovakia, Italy, Austria, Bulgaria, Portugal, Greece, Czechia, Sweden
30/10/2026
Phase I/II
Aarhus Universitet
Cardiovascular Diseases
Denmark
29/10/2026
Phase I
Argenx
Musculoskeletal Diseases
Slovenia, Latvia, Denmark, Germany, Belgium, Norway, Spain, Poland, Lithuania, Italy, France, Netherlands
27/10/2026
Phase III
Celcuity Inc.
Neoplasms
Finland, Bulgaria, Portugal, Germany, Greece, Romania, Poland, Hungary, Czechia, Italy, Denmark, Belgium, France, Spain
27/10/2026
Phase I
A Study of RO7821657 in Participants with Solid Tumors
2026-526150-14-00Advanced and/or Metastatic Solid Tumors
F. Hoffmann-La Roche AG
Neoplasms
France, Denmark, Spain
27/10/2026
Phase II
F. Hoffmann-La Roche AG
Nervous System Diseases
Spain, Belgium, Denmark, France, Poland, Italy, Germany, Ireland
27/10/2026
Phase II
Vico Therapeutics B.V.
Nervous System Diseases
Denmark, France, Netherlands, Germany
26/10/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Portugal, Bulgaria, Germany, Croatia, Hungary, Czechia, Romania, Spain, Italy, Denmark, Slovakia, Greece, Poland
23/10/2026
Phase II
University Of Leicester
Respiratory Tract Diseases
Spain, Netherlands, Italy, Denmark
22/10/2026
Phase III
Bristol-Myers Squibb Services Unlimited Company
Mental Disorders
Romania, Bulgaria, Poland, Denmark, Spain
20/10/2026
Phase III
Novo Nordisk A/S
Hemic and Lymphatic Diseases
France, Italy, Greece, Poland, Spain, Denmark, Germany
19/10/2026
Phase II
Novartis Pharma AG
Immune System Diseases
Portugal, Bulgaria, Belgium, Spain, Denmark, France, Slovakia, Poland, Hungary, Italy, Netherlands, Germany, Austria
15/10/2026
Phase II
Glaxosmithkline Research & Development Limited
Digestive System Diseases
Spain, Denmark, Italy, Poland, France, Germany, Greece
12/10/2026
Phase II
Universitair Medisch Centrum Groningen
Nutritional and Metabolic Diseases
Finland, Denmark
09/10/2026
Phase III
Prediction and Prevention of Bloodstream Infections After Kidney Transplantation - the PREDICT Study
2026-527337-63-00Bacterial urinary tract infections and bloodstream infectio…
Region Hovedstaden
Bacterial Infections and Mycoses
Denmark
05/10/2026
Phase II
Merck Sharp & Dohme LLC
Neoplasms
Belgium, Spain, Denmark, Italy, France
05/10/2026
Phase III
F. Hoffmann-La Roche AG
Nervous System Diseases
Spain, Denmark
29/09/2026
Phase II
Expedition Therapeutics Inc.
Respiratory Tract Diseases
Italy, Germany, Spain, Poland, Czechia, Romania, Hungary, Denmark, Bulgaria
29/09/2026
Phase III
Regeneron Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Spain, Slovakia, Hungary, Czechia, Romania, Estonia, Austria, France, Belgium, Sweden, Italy, Latvia, Poland, Bulgaria, Greece, Germany, Denmark, Lithuania, Netherlands
29/09/2026
Phase III
Kardigan Inc.
Cardiovascular Diseases
Poland, Sweden, Belgium, France, Spain, Hungary, Denmark, Italy, Netherlands
28/09/2026
Phase III
Dianthus Therapeutics Inc.
Immune System Diseases
Czechia, Portugal, Austria, Bulgaria, Germany, France, Latvia, Poland, Italy, Spain, Denmark
28/09/2026
Phase III
Almirall S.A.
Skin and Connective Tissue Diseases
Poland, Germany, Portugal, France, Spain, Denmark
22/09/2026
Phase II
Agomab Spain S.L.U.
Digestive System Diseases
France, Germany, Poland, Spain, Czechia, Denmark, Austria, Italy, Belgium, Netherlands
21/09/2026
Phase III
Amgen Inc.
Nutritional and Metabolic Diseases
Czechia, Spain, Poland, Denmark, Germany, Italy, Belgium, Finland
21/09/2026
Phase III
Glaxosmithkline Research & Development Limited
Neoplasms
Denmark, Netherlands, Italy, Spain, France, Portugal, Greece, Poland, Germany, Belgium, Norway, Czechia
21/09/2026
Phase III
Celea Therapeutics Inc.
Respiratory Tract Diseases
Greece, Italy, Czechia, France, Portugal, Denmark, Spain, Poland, Germany, Romania, Belgium, Netherlands
18/09/2026
Phase II
Region Hovedstaden
Mental Disorders
Denmark
17/09/2026
Phase III
Novo Nordisk A/S
Cardiovascular Diseases
Denmark, Czechia, Greece, France, Italy, Germany, Spain, Poland, Netherlands, Bulgaria
16/09/2026
Phase II
Oslo Universitetssykehus HF
Respiratory Tract Diseases
Sweden, Norway, Denmark
16/09/2026
Phase II
Eli Lilly & Co.
Respiratory Tract Diseases
Denmark, France, Romania, Czechia, Poland, Hungary, Germany, Austria
15/09/2026
Phase IV
Region Hovedstaden
Anesthesia and Analgesia
Denmark
08/09/2026
Phase II
Steno Diabetes Center Copenhagen
Hormonal diseases
Denmark
08/09/2026
Phase III
Zoledronic acid as prophylaxis against glucocorticoid-induced osteoporosis in lymphoma
2026-527220-27-00Large B-cell lymphomas, transformations of indolent B-cell …
Region Nordjylland
Neoplasms
Denmark
07/09/2026
Phase I
F. Hoffmann-La Roche AG
Neoplasms
Spain, Poland, Romania, Hungary, Germany, Italy, Belgium, Netherlands, Denmark, France
07/09/2026
Phase IV
Vaestra Goetalandsregionen, University Of Gothenburg
Cardiovascular Diseases
Denmark, Sweden, Norway
02/09/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Belgium, Czechia, Hungary, Sweden, Lithuania, Croatia, Netherlands, Slovakia, Poland, Austria, Norway, France, Italy, Bulgaria, Spain, Germany, Romania, Slovenia, Estonia, Portugal, Greece, Denmark
02/09/2026
Phase III
Region Midtjylland
Bacterial Infections and Mycoses
Denmark
02/09/2026
Phase II
Dompe' Farmaceutici S.p.A.
Eye Diseases
Denmark, Italy, Germany, Hungary, Netherlands, Spain, Belgium, France, Portugal
01/09/2026
Phase II
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Hemic and Lymphatic Diseases
Czechia, Denmark, Croatia, Spain, Sweden, Finland, Portugal, Ireland, Netherlands, Belgium, Norway
31/08/2026
Phase II
Region Midtjylland, Region Sjaelland
Immune System Diseases
Denmark
31/08/2026
Phase IV
S-KETamine vs. propofol for prehospital sedation of patients with severe Acute Brain Injury: The KETABI randomised trial
2026-525588-41-00traumatic brain injury, subarachnoid haemorrhage, intracere…
Region Hovedstaden
Pathological Conditions, Signs and Symptoms
Denmark
27/08/2026
Phase II
Contineum Therapeutics Inc.
Respiratory Tract Diseases
Italy, Belgium, Denmark, Austria, Greece, Germany, France, Netherlands, Portugal, Poland, Spain
26/08/2026
Phase II
Genmab A/S
Neoplasms
Italy, Belgium, France, Spain, Denmark, Netherlands, Germany
26/08/2026
Phase IV
Region Hovedstaden
Bacterial Infections and Mycoses
Denmark
25/08/2026
Phase IV
Gentofte Hospital
Skin and Connective Tissue Diseases
Denmark
24/08/2026
Phase III
Norges Teknisk-Naturvitenskapelige Universitet NTNU
Neoplasms
Denmark, Finland, Estonia, Germany, Lithuania, Sweden, Norway, Netherlands
17/08/2026
Phase II
Odense University Hospital
Neoplasms
Denmark
14/08/2026
Phase II
Celgene Corp.
Immune System Diseases
Germany, Denmark
10/08/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Netherlands, Belgium, Greece, Poland, Spain, Denmark, France, Bulgaria, Sweden
10/08/2026
Phase IV
The RHINOME study
2026-527032-14-00Severe asthma
Region Hovedstaden
Respiratory Tract Diseases
Denmark
10/08/2026
Phase II
Region Midtjylland
Therapeutics
Denmark
10/08/2026
Phase III
Argenx
Hormonal diseases
Italy, Czechia, Spain, Denmark, Belgium, Romania, Latvia, France, Germany, Greece, Sweden, Poland, Lithuania, Bulgaria
07/08/2026
Phase IV
Gentofte Hospital, Moderna Inc.
Virus Diseases
Denmark, Spain
07/08/2026
Phase III
AstraZeneca AB
Respiratory Tract Diseases
Denmark, Belgium, France, Italy, Netherlands, Austria, Poland
04/08/2026
Phase II
AstraZeneca AB
Respiratory Tract Diseases
Poland, Hungary, Netherlands, Germany, Spain, Greece, Bulgaria, Italy, France, Denmark
04/08/2026
Phase III
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Skin and Connective Tissue Diseases
Denmark, Hungary, Sweden, Netherlands, Germany, Belgium, France, Greece, Norway, Finland, Czechia, Portugal, Bulgaria, Spain, Austria, Romania, Croatia, Poland, Estonia, Italy, Lithuania
03/08/2026
Phase III
Janssen Cilag International
Immune System Diseases
France, Bulgaria, Romania, Slovakia, Norway, Denmark, Greece, Italy, Austria, Poland, Netherlands, Czechia, Germany, Belgium, Spain, Hungary, Portugal
03/08/2026
Phase II
Aalborg University Hospital
Therapeutics
Denmark
01/08/2026
Phase II
Ribocure Pharmaceuticals AB
Cardiovascular Diseases
Norway, Denmark, Poland, Sweden
24/07/2026
Phase III
AstraZeneca AB
Cardiovascular Diseases
Czechia, Italy, Hungary, Romania, Bulgaria, Sweden, Denmark, Poland, Spain, Norway, Finland, Greece, France, Germany
24/07/2026
Phase III
Ipsen Bioscience Inc.
Digestive System Diseases
Spain, Sweden, Germany, Romania, Finland, Portugal, Austria, Italy, Denmark, Czechia, France, Netherlands, Poland, Belgium, Norway
21/07/2026
Phase III
Novartis Pharma AG
Nervous System Diseases
Norway, Poland, Spain, Sweden, Bulgaria, Netherlands, Finland, Portugal, Austria, Italy, Greece, Ireland, Czechia, France, Romania, Belgium, Germany, Denmark, Slovakia, Hungary
20/07/2026
Phase III
Arrowhead Pharmaceuticals Inc.
Cardiovascular Diseases
Netherlands, Denmark, Norway, Sweden, Poland
20/07/2026
Phase III
Merck Healthcare KGaA
Neoplasms
Belgium, Germany, France, Denmark, Poland, Spain, Netherlands, Italy, Austria
14/07/2026
Phase III
Revolution Medicines Inc.
Digestive System Diseases
Poland, Belgium, Norway, Sweden, Austria, Germany, Denmark, Netherlands, France, Italy, Spain
14/07/2026
Phase IV
Region Hovedstaden
Female Urogenital Diseases and Pregnancy Complications
Denmark
14/07/2026
Phase I
A Phase 1, First-in-human, Dose Escalation Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
2026-525234-39-00Relapsed or Refractory higher-risk myelodysplastic syndrome…
Janssen Cilag International
Neoplasms
France, Spain, Germany, Denmark, Belgium
13/07/2026
Phase III
Institut Gustave Roussy
Neoplasms
Sweden, Poland, Denmark, Finland, Netherlands, Italy, France, Spain
08/07/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Denmark, Sweden, Poland, Estonia, Portugal, Latvia, Spain, Hungary, Germany, Finland, Italy, Belgium, France
06/07/2026
Phase IV
Region Hovedstaden
Digestive System Diseases
Denmark
06/07/2026
Phase III
The RELEASE Trial: Reconsidering Long-Term Aspirin in the Elderly in Secondary Prevention of Cardiovascular Disease
2026-525442-30-00Ischemic heart disease/Chronic coronary syndrome (Myocardia…
Odense University Hospital
Cardiovascular Diseases
Denmark
06/07/2026
Phase II
Kobenhavns Universitet, Koebenhavns Universitet
Mental Disorders
Denmark
03/07/2026
Phase I
Region Sjaelland
Female Urogenital Diseases and Pregnancy Complications
Denmark
03/07/2026
Phase I/II
Syddansk Universitet (University of Southern Denmark)
Nervous System Diseases
Denmark
01/07/2026
Phase III
Genmab A/S
Neoplasms
Finland, Belgium, Hungary, France, Denmark, Austria, Germany, Italy, Spain, Czechia, Norway, Poland
01/07/2026
Phase III
Insmed Inc.
Respiratory Tract Diseases
Greece, France, Italy, Belgium, Denmark, Germany, Poland, Czechia, Portugal, Austria, Spain, Romania
30/06/2026
Phase III
Renaissance Pharma Limited
Nervous System Diseases
France, Spain, Denmark, Ireland, Germany
30/06/2026
Phase IV
Region Hovedstaden
Mental Disorders
Denmark
29/06/2026
Phase III
Self-Assessment Method for Statin side-effects Or Nocebo 2
2025-524955-30-01Cardiovascular diseases
Copenhagen University Hospital, Region Hovedstaden
Musculoskeletal Diseases
Denmark
28/06/2026
Phase III
Incyte Corp.
Neoplasms
Poland, Italy, Netherlands, Sweden, Denmark, Finland, Spain, France, Germany, Belgium, Norway, Austria
26/06/2026
Phase IV
Region Hovedstaden
Hemic and Lymphatic Diseases
Denmark
25/06/2026
Phase III
Region Hovedstaden
Nervous System Diseases
Denmark
25/06/2026
Phase II
Rigshospitalet, Elpida Therapeutics SPC
Nervous System Diseases
Denmark
23/06/2026
Phase III
Zenas Biopharma (USA) LLC
Nervous System Diseases
Germany, Bulgaria, Netherlands, Sweden, Portugal, Croatia, Italy, Austria, Spain, Poland, France, Denmark, Hungary, Romania, Estonia, Slovakia, Belgium, Czechia, Norway, Lithuania, Greece, Slovenia
22/06/2026
Phase II
Angitia Inc. Ltd.
Musculoskeletal Diseases
Netherlands, France, Denmark
22/06/2026
Phase II
Latigo Biotherapeutics Inc.
Musculoskeletal Diseases
Denmark
22/06/2026
Phase I
Mipsalus ApS
Nutritional and Metabolic Diseases
Denmark
17/06/2026
Phase III
Bristol-Myers Squibb Services Unlimited Company
Respiratory Tract Diseases
Finland, Portugal, Hungary, Ireland, Poland, Greece, France, Belgium, Denmark, Italy, Spain, Netherlands, Austria, Germany
17/06/2026
Phase I
Incyte Corp.
Neoplasms
Italy, Belgium, Denmark
16/06/2026
Phase III
ML Bio Solutions Inc.
Musculoskeletal Diseases
Germany, Denmark, Netherlands, Italy, Norway
15/06/2026
Phase III
Merck Sharp & Dohme LLC
Neoplasms
Greece, Netherlands, Sweden, France, Italy, Spain, Denmark
12/06/2026
Phase IV
Odense University Hospital
Musculoskeletal Diseases
Denmark
12/06/2026
Phase I
Novartis Pharma AG
Neoplasms
Denmark
10/06/2026
Phase III
Zai Lab (US) LLC
Neoplasms
Belgium, Czechia, Germany, Denmark, Greece, Netherlands, Poland, Spain, Austria, Italy, France, Croatia, Romania, Norway
08/06/2026
Phase IV
Measles-mumps-rubella vaccine (MMR) at 6 months of age: Long-term follow-up
2026-526160-21-00Prevention of measles, mumps, and rubella by vaccination
Rigshospitalet
Virus Diseases
Denmark
08/06/2026
Phase I
Bayer Consumer Care AG
Neoplasms
Finland, Spain, Sweden, Italy, Denmark, Netherlands, Belgium
08/06/2026
Phase III
Eyebiotech Limited
Eye Diseases
Austria, Slovakia, Portugal, Czechia, Hungary, Spain, France, Denmark, Italy, Croatia
05/06/2026
Phase IV
Pulmonary Embolism & Anticoagulation Evaluation in Cancer Patient - PEACE
2025-524110-28-00Incidental Subsegmental Pulmonary Embolism in cancer patien…
Region Hovedstaden
Cardiovascular Diseases
Denmark
04/06/2026
Phase III
F. Hoffmann-La Roche AG
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
France, Austria, Poland, Netherlands, Spain, Denmark, Italy, Germany, Hungary
01/06/2026
Phase III
F. Hoffmann-La Roche AG
Hemic and Lymphatic Diseases
Hungary, Spain, Ireland, Poland, Austria, Germany, Denmark, Belgium, Netherlands, Italy, France
01/06/2026
Phase II
Vertex Pharmaceuticals Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain, Sweden, Germany, Italy, Belgium, Czechia, Ireland, Portugal, Netherlands, France, Denmark
29/05/2026
Phase II
F. Hoffmann-La Roche AG
Immune System Phenomena
Italy, Spain, Germany, France, Denmark, Poland, Belgium
27/05/2026
Phase III
Janssen Cilag International
Immune System Diseases
Slovakia, Germany, Denmark, France, Spain, Italy, Netherlands, Belgium, Poland, Sweden, Austria, Czechia, Hungary
27/05/2026
Phase I/II
Merck Sharp & Dohme LLC
Neoplasms
France, Spain, Sweden, Germany, Italy, Belgium, Denmark, Czechia, Hungary, Netherlands, Slovakia
26/05/2026
Phase I/II
Orion Corporation
Neoplasms
Finland, Denmark, Spain, France
22/05/2026
Phase II
Pharming Technologies B.V.
Metabolism
Belgium, Germany, Czechia, Spain, Denmark, Italy, France, Netherlands
21/05/2026
Phase I
Glaxosmithkline Research & Development Limited
Neoplasms
Spain, Denmark, Finland, France
21/05/2026
Phase III
Novartis Pharma AG
Immune System Diseases
Portugal, Greece, Germany, Hungary, France, Spain, Bulgaria, Slovakia, Poland, Czechia, Belgium, Italy, Romania, Denmark
20/05/2026
Phase II
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Nutritional and Metabolic Diseases
Portugal, Greece, Italy, Poland, Estonia, Slovakia, Sweden, Denmark, Belgium, Norway, Romania, France, Spain, Germany, Netherlands, Croatia
19/05/2026
Phase III
Incyte Corp.
Neoplasms
Poland, France, Denmark, Norway, Spain, Germany, Belgium, Netherlands, Austria, Italy
19/05/2026
Phase II
Region Hovedstaden
Neoplasms
Denmark
18/05/2026
Phase II
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Spain, France, Denmark
18/05/2026
Phase III
Zenas Biopharma (USA) LLC
Nervous System Diseases
Italy, Finland, Bulgaria, Greece, Belgium, Estonia, Portugal, Spain, Germany, France, Czechia, Slovakia, Romania, Croatia, Poland, Austria, Netherlands, Denmark, Sweden, Hungary
18/05/2026
Phase I/II
Aurinia Pharmaceuticals Inc.
Immune System Diseases
Poland, Spain, Denmark, Latvia, Italy
15/05/2026
Phase III
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Portugal, Spain, Poland, Sweden, Italy, Czechia, France, Netherlands, Finland, Denmark, Austria, Germany, Belgium, Norway
13/05/2026
Phase II
Odense University Hospital
Therapeutics
Denmark
13/05/2026
Phase I
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Netherlands, Denmark
11/05/2026
Phase III
Region Hovedstaden
Musculoskeletal Diseases
Denmark
11/05/2026
Phase I
F. Hoffmann-La Roche AG
Nervous System Diseases
Italy, Poland, Denmark, Germany, Portugal, Spain
11/05/2026
Phase III
Eli Lilly & Co.
Neoplasms
Netherlands, Hungary, France, Austria, Poland, Italy, Denmark, Romania, Greece, Norway, Czechia, Belgium, Spain, Ireland, Germany
11/05/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Germany, Netherlands, Portugal, Denmark, Sweden, Finland, France, Spain, Austria, Italy, Hungary, Romania, Belgium, Czechia, Poland
11/05/2026
Phase II
Region Sjaelland
Digestive System Diseases
Denmark
07/05/2026
Phase IV
Colchicine Assessment of Low-grade Inflammation and Biomarker Response in Atherosclerosis with Targeted Evaluation
2026-525547-32-01Ischemic Heart Disease, Coronary Artery Disease, Chronic Co…
Region Hovedstaden
Cardiovascular Diseases
Denmark
06/05/2026
Phase III
Janssen Cilag International
Immune System Diseases
Denmark, Hungary, Portugal, Italy, Norway, Greece, Slovakia, Czechia, France, Poland, Bulgaria, Germany, Spain, Romania, Finland
05/05/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Denmark, France, Germany, Belgium
04/05/2026
Phase III
Merck Sharp & Dohme LLC
Neoplasms
Denmark, Spain, Netherlands, Germany, France, Czechia, Poland, Italy, Greece
04/05/2026
Phase III
Inhibikase Therapeutics Inc.
Cardiovascular Diseases
Spain, Poland, Italy, Belgium, Latvia, Denmark, Czechia, Germany, France, Netherlands, Portugal, Ireland, Austria, Greece, Lithuania
28/04/2026
Phase III
Merck Sharp & Dohme LLC
Neoplasms
Czechia, Spain, Poland, Belgium, Finland, Germany, France, Netherlands, Hungary, Denmark
28/04/2026
Phase III
Dyne Therapeutics Inc.
Nervous System Diseases
Netherlands, Spain, Italy, Denmark, Germany, Belgium, France
28/04/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Slovakia, Austria, Spain, Romania, Portugal, Italy, Denmark, Belgium, Sweden, Poland, Netherlands, Croatia, Hungary, Bulgaria
28/04/2026
Phase III
OncoZenge AB
Anesthesia and Analgesia
Germany, Denmark, Norway, Sweden
28/04/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Belgium, Germany, Bulgaria, France, Spain, Denmark, Italy, Netherlands
27/04/2026
Phase IV
Eli Lilly & Co.
Immune System Diseases
Spain, Denmark, Germany, Italy, Poland
27/04/2026
Phase II
Methylphenidate for Early Awakening in Coma (MEAWAKE)
2025-524937-19-00Coma due to acute brain injury
Rigshospitalet
Nervous System Diseases
Austria, Denmark, Germany, France
27/04/2026
Phase I/II
Fortvita Biologics (USA) Inc.
Respiratory Tract Diseases
Poland, Denmark, Spain
27/04/2026
Phase IV
Infusion of Furosemide to Improve Diuretic Efficiency in Acute Heart Failure (INFUSE-AHF)
2025-523589-26-00Acute heart failure with volume overload
Region Midtjylland
Cardiovascular Diseases
Denmark
24/04/2026
Phase I/II
Institut De Recherches Internationales Servier IRIS
Neoplasms
France, Spain, Denmark, Italy
21/04/2026
Phase III
Novo Nordisk A/S
Cardiovascular Diseases
Denmark, Greece, Bulgaria, Italy, Netherlands, Spain, Poland, Czechia, Germany, France
17/04/2026
Phase I/II
Glaxosmithkline Research & Development Limited
Neoplasms
Italy, Denmark, Spain, Sweden, Netherlands, France
14/04/2026
Phase III
Rigshospitalet
Nervous System Diseases
Denmark
13/04/2026
Phase II
Enlivex Therapeutics Ltd.
Musculoskeletal Diseases
Denmark, Poland
13/04/2026
Phase III
Glaxosmithkline Research & Development Limited
Respiratory Tract Diseases
Germany, Belgium, Netherlands, Denmark, Spain, Greece, Poland, Hungary, France, Italy, Bulgaria, Romania
07/04/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Italy, Greece, Spain, Bulgaria, Denmark, Poland
07/04/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Greece, Poland, Spain, Bulgaria, Italy, Denmark
07/04/2026
Phase II
Herlev Hospital
Male Urogenital Diseases
Denmark
07/04/2026
Phase I
Rituximab for Treatment of Checkpoint Inhibitor Induced Immune Related Adverse Events
2026-525728-18-00All CTCAE (v. 6.0) grade 2-4 immune-related adverse events
Region Hovedstaden
Immune System Diseases
Denmark
30/03/2026
Phase II
Region Hovedstaden
Behavior and Behavior Mechanisms
Denmark
30/03/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Denmark, Poland, Spain, Germany
30/03/2026
Phase IV
Evidence based empirical antibiotic treatment for urinary tract infections requiring hospitalisation - TRI-AB trial
2024-520251-24-00Complicated urinary tract infections (cUTI) requiring hospi…
Odense University Hospital
Bacterial Infections and Mycoses
Denmark
27/03/2026
Phase III
AstraZeneca AB
Pathological Conditions, Signs and Symptoms
Ireland, Greece, Czechia, France, Sweden, Belgium, Denmark, Spain, Italy, Germany
27/03/2026
Phase III
Genmab A/S
Neoplasms
Poland, Denmark, Finland, Lithuania, France, Germany, Spain, Belgium, Greece, Norway, Italy
26/03/2026
Phase I/II
Syddansk Universitet (University of Southern Denmark)
Nervous System Diseases
Denmark
26/03/2026
Phase I
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
2024-519862-33-01Platinum-resistant ovarian cancer (PROC), Advanced renal ce…
Oncusp Therapeutics Inc.
Neoplasms
Denmark, Spain
23/03/2026
Phase II
Eli Lilly & Co.
Digestive System Diseases
Hungary, Spain, Denmark, Netherlands, Poland, Romania, Germany, Italy, Austria
18/03/2026
Phase III
University Of Cologne
Neoplasms
Austria, Germany, Denmark, Ireland, Netherlands, Italy
18/03/2026
Phase III
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Male Urogenital Diseases
Germany, Croatia, Poland, Sweden, Portugal, Netherlands, Italy, Denmark, Slovakia, Spain, Norway, Romania, Belgium, Greece, France
17/03/2026
Phase IV
Rigshospitalet
Neoplasms
Denmark
17/03/2026
Phase I/II
Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE)
2024-516896-34-00progressive/relapsed/refractory pediatric low-grade glioma …
Universitaetsklinikum Heidelberg AöR
Nervous System Diseases
Denmark, Czechia, Austria, Sweden, Germany
17/03/2026
Phase III
Celldex Therapeutics Inc.
Skin and Connective Tissue Diseases
Croatia, France, Netherlands, Bulgaria, Portugal, Slovakia, Hungary, Italy, Greece, Germany, Czechia, Lithuania, Spain, Belgium, Denmark, Poland
16/03/2026
Phase IV
Steno Diabetes Center Copenhagen
Hormonal diseases
Denmark
16/03/2026
Phase I
CRISPR Therapeutics AG
Hemic and Lymphatic Diseases
Spain, Germany, France, Denmark, Italy, Netherlands
12/03/2026
Phase III
Prehospital pulse-dose glucocorticoid in patients with STEMI – the PULSE-MI 2 trial
2025-524320-21-00ST-segment Elevation Myocardial Infarction
Rigshospitalet
Cardiovascular Diseases
Denmark
11/03/2026
Phase I/II
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Neoplasms
Denmark, Belgium, Netherlands
10/03/2026
Phase IV
Region Midtjylland
Not possible to specify
Denmark
09/03/2026
Phase I/II
Region Midtjylland
Immune System Diseases
Denmark
09/03/2026
Phase I
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Denmark
06/03/2026
Phase II
Up-titration of sulfonylurea (SU) in individuals with HNF1A- and HNF4A-MODY – A Steno MODERN-MODY project (MM-SUUP)
2025-524679-22-00Maturity-onset diabetes of the young type 3 (HNF1A-MODY), M…
Steno Diabetes Center Copenhagen
Hormonal diseases
Denmark
04/03/2026
Phase IV
Gentofte Hospital, GlaxoSmithKline Biologicals
Skin and Connective Tissue Diseases
Denmark
04/03/2026
Phase III
Novartis Pharma AG
Nervous System Diseases
Denmark, Slovenia, Netherlands, Portugal, Ireland, Sweden, Croatia, Greece, Germany, Latvia, Czechia, Spain, Romania, Belgium, Austria, Lithuania, Slovakia, Poland, Estonia, Bulgaria, France, Italy, Hungary, Finland, Norway
03/03/2026
Phase IV
Region Midtjylland
Otorhinolaryngologic Diseases
Denmark
03/03/2026
Phase II
Region Midtjylland
Nutritional and Metabolic Diseases
Denmark
02/03/2026
Phase II
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Poland, Italy, Belgium, Sweden, Hungary, France, Germany, Spain, Denmark
02/03/2026
Phase I
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
2025-524334-26-01Endometrial cancer (EC), Advanced or metastatic breast canc…
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Denmark
26/02/2026
Phase I
Region Hovedstaden
Neoplasms
Denmark
23/02/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Germany, Hungary, Italy, Belgium, Czechia, Finland, Spain, Austria, Sweden, France, Denmark, Netherlands
23/02/2026
Phase I
A Phase 1 Study of IM-1021 in Participants with Advanced Cancer
2025-523160-20-00Advanced B-cell lymphomas, Advanced solid tumors
Immunome Inc.
Neoplasms
France, Spain, Denmark, Italy
16/02/2026
Phase II
Pediatric Research International GmbH
Neoplasms
Denmark, Italy, Czechia, Sweden, Poland, Netherlands, Germany, Austria
16/02/2026
Phase I
Novartis Pharma AG
Neoplasms
Germany, Portugal, France, Spain, Denmark
16/02/2026
Phase II
AstraZeneca AB
Bacterial Infections and Mycoses
Greece, Spain, France, Germany, Italy, Hungary, Denmark, Sweden
16/02/2026
Phase III
Region Vaesterbotten, Umea University
Otorhinolaryngologic Diseases
Sweden, Denmark, Norway
11/02/2026
Phase III
Argenx
Nervous System Diseases
Czechia, Denmark, Poland, Slovenia, Netherlands, Austria, Estonia, Slovakia, Hungary, Finland, Bulgaria, France, Italy, Greece, Romania
10/02/2026
Phase II
GSK PLC
Respiratory Tract Diseases
Denmark, France, Spain, Italy, Germany, Poland
09/02/2026
Phase I
Region Hovedstaden
Eye Diseases
Denmark
04/02/2026
Phase III
Alnylam Pharmaceuticals Inc.
Cardiovascular Diseases
Belgium, Hungary, Czechia, Austria, Germany, France, Greece, Spain, Romania, Netherlands, Italy, Poland, Slovakia, Sweden, Portugal, Denmark, Bulgaria
03/02/2026
Phase II
Sab Biotherapeutics Inc.
Nutritional and Metabolic Diseases
Austria, Germany, Poland, Italy, Denmark, Spain, Belgium, Finland, France, Lithuania, Slovenia
02/02/2026
Phase III
Kardigan Inc.
Cardiovascular Diseases
Spain, Denmark, Belgium, Hungary, Italy, Poland, France, Sweden, Netherlands
30/01/2026
Phase III
Ideaya Biosciences Inc.
Eye Diseases
France, Spain, Poland, Italy, Czechia, Belgium, Austria, Netherlands, Denmark, Germany, Slovenia
29/01/2026
Phase III
Insmed Inc.
Respiratory Tract Diseases
Portugal, Italy, Czechia, Poland, Denmark, Greece, Germany, Romania, Spain, France, Belgium, Austria
26/01/2026
Phase III
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Austria, Portugal, Netherlands, Greece, Belgium, Spain, Germany, France, Romania, Sweden, Italy, Denmark
19/01/2026
Phase III
Bristol-Myers Squibb Services Unlimited Company
Immune System Diseases
Romania, Bulgaria, Germany, Spain, Czechia, France, Hungary, Italy, Sweden, Poland, Denmark, Belgium
19/01/2026
Phase I
Region Midtjylland
Virus Diseases
Germany, Denmark
19/01/2026
Phase III
Region Hovedstaden
Mental Disorders
Denmark
16/01/2026
Phase I
Genmab A/S
Neoplasms
Denmark, Spain, Italy, Netherlands
16/01/2026
Phase III
Bristol-Myers Squibb Services Unlimited Company
Mental Disorders
Romania, Poland, France, Italy, Denmark, Bulgaria
15/01/2026
Phase III
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Neoplasms
Belgium, Netherlands, Germany, Austria, Denmark, Estonia, Finland, Ireland, Italy, Lithuania, Spain, Sweden, Norway, Poland
15/01/2026
Phase II
AstraZeneca AB
Not possible to specify
Germany, France, Spain, Italy, Belgium, Czechia, Greece, Denmark, Hungary
14/01/2026
Phase II
Gentofte Hospital
Skin and Connective Tissue Diseases
Denmark
12/01/2026
Phase III
F. Hoffmann-La Roche AG
Nervous System Diseases
France, Austria, Portugal, Netherlands, Poland, Germany, Spain, Denmark, Italy
23/12/2025
Phase III
Khondrion B.V.
Nervous System Diseases
Italy, Germany, France, Netherlands, Denmark
19/12/2025
Phase III
Region Skane
Cardiovascular Diseases
Sweden, Denmark
16/12/2025
Phase III
Universita Degli Studi Di Milano Bicocca
Neoplasms
France, Lithuania, Norway, Finland, Spain, Italy, Czechia, Germany, Hungary, Slovakia, Denmark, Austria, Netherlands
09/12/2025
Phase III
Novo Nordisk A/S
Cardiovascular Diseases
Germany, France, Belgium, Italy, Denmark, Netherlands, Spain, Czechia, Sweden
09/12/2025
Phase III
Charite Universitaetsmedizin Berlin KöR
Hemic and Lymphatic Diseases
Netherlands, Czechia, Italy, Spain, Denmark, Austria, Norway, Sweden, Germany, France, Finland, Belgium, Slovenia
09/12/2025
Phase IV
Nordsjaellands Hospital
Virus Diseases
Denmark
08/12/2025
Phase III
Zealand Pharma A/S
Digestive System Diseases
Finland, France, Belgium, Germany, Hungary, Spain, Austria, Netherlands, Italy, Denmark, Czechia, Norway, Poland, Sweden, Estonia
04/12/2025
Phase III
UCB Biopharma
Immune System Diseases
Czechia, Denmark, Spain, Poland, Germany, Hungary, Italy, France
02/12/2025
Phase III
Merck Sharp & Dohme LLC
Cardiovascular Diseases
Czechia, Germany, Sweden, Greece, Croatia, Belgium, Poland, Spain, Portugal, Italy, Denmark, France, Netherlands
01/12/2025
Phase III
Argenx
Nervous System Diseases
Czechia, Bulgaria, Netherlands, Hungary, Sweden, Slovakia, Slovenia, Greece, Norway, Poland, Italy, Spain, Estonia, Denmark, France, Romania, Portugal, Austria, Germany
01/12/2025
Phase II
Shionogi B.V.
Nutritional and Metabolic Diseases
Belgium, Germany, Denmark, France, Italy, Spain, Netherlands
01/12/2025
Phase III
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Czechia, Austria, Belgium, Ireland, Spain, Germany, Romania, Netherlands, Slovakia, Greece, Poland, Italy, Denmark, France, Sweden
28/11/2025
Phase III
Glaxosmithkline Research & Development Limited
Respiratory Tract Diseases
Slovakia, Denmark, France, Sweden, Ireland, Belgium, Netherlands, Spain, Croatia, Germany, Poland, Hungary, Norway, Portugal
24/11/2025
Phase III
REVERsal to normoglycemia by Treating PREDIABETES: the REVERT-PREDIABETES trial
2025-522970-35-00Coronary artery disease, Prediabetes
Region Midtjylland
Cardiovascular Diseases
Denmark
23/11/2025
Phase II
F. Hoffmann-La Roche AG
Immune System Phenomena
Italy, Denmark, France, Poland, Germany, Spain, Belgium
23/11/2025
Phase III
Pfizer Inc.
Neoplasms
Greece, Italy, Belgium, Slovakia, Czechia, Germany, France, Poland, Denmark, Spain, Netherlands, Sweden, Finland, Bulgaria
17/11/2025
Phase III
AstraZeneca AB
Neoplasms
Italy, Netherlands, Lithuania, Finland, Greece, Austria, Belgium, Hungary, Spain, Poland, Czechia, Germany, France, Denmark, Slovenia
17/11/2025
Phase III
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL.
2025-522052-13-00Framework for Optimizing, Refining, and Unifying Management…
Ospedale Pediatrico Bambino Gesu
Hemic and Lymphatic Diseases
Germany, Denmark, Finland, Norway, Austria, Italy, Poland, France, Czechia, Belgium, Croatia, Hungary, Lithuania, Sweden, Netherlands, Slovakia, Spain
17/11/2025
Phase IV
Rigshospitalet
Respiratory Tract Diseases
Denmark
14/11/2025
Phase II
Merck Sharp & Dohme LLC
Neoplasms
Norway, Spain, Sweden, Italy, Denmark, France, Poland, Germany, Greece
12/11/2025
Phase III
Relay Therapeutics Inc.
Neoplasms
Hungary, Spain, Italy, Belgium, Netherlands, Austria, Germany, Greece, Czechia, Denmark, Poland, Bulgaria, Portugal, France, Ireland, Romania
11/11/2025
Phase III
Annexon Inc.
Immune System Diseases
Denmark, France, Spain
11/11/2025
Phase III
Merck Sharp & Dohme LLC
Neoplasms
Greece, Germany, France, Italy, Croatia, Denmark, Czechia, Austria, Belgium, Ireland, Spain, Poland
10/11/2025
Phase II
Latigo Biotherapeutics Inc.
Musculoskeletal Diseases
Denmark
10/11/2025
Phase I/II
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Denmark, Spain
07/11/2025
Phase II
Arctic Therapeutics hf.
Skin and Connective Tissue Diseases
Denmark
07/11/2025
Phase III
Helse Bergen HF, St. Olavs Hospital HF
Nervous System Diseases
Norway, Denmark
04/11/2025
Phase III
Helse Bergen HF, St. Olavs Hospital HF
Nervous System Diseases
Denmark, Norway
04/11/2025
Phase III
F. Hoffmann-La Roche AG
Nervous System Diseases
Poland, France, Germany, Netherlands, Spain, Italy, Denmark
04/11/2025
Phase III
F. Hoffmann-La Roche AG
Nervous System Diseases
Spain, Poland, Italy, Denmark, France, Germany
04/11/2025
Phase III
Avidity Biosciences Inc.
Musculoskeletal Diseases
Italy, France, Germany, Spain, Denmark, Netherlands
04/11/2025
Phase I/II
Glaxosmithkline Research & Development Limited
Neoplasms
Estonia, Czechia, Spain, Romania, Italy, Denmark, Belgium, Greece
03/11/2025
Phase II
AstraZeneca AB
Respiratory Tract Diseases
Netherlands, Italy, Greece, Denmark, Belgium, Spain, France, Germany
31/10/2025
Phase I
University College London
Female Urogenital Diseases and Pregnancy Complications
France, Spain, Austria, Denmark
28/10/2025
Phase I
Amgen Inc.
Neoplasms
France, Netherlands, Germany, Denmark, Spain, Italy, Belgium
28/10/2025
Phase IV
Gentofte Hospital, Austin Health
Immune System Diseases
Belgium, Denmark
28/10/2025
Phase II
Immunovant Sciences GmbH
Immune System Diseases
Austria, Hungary, Slovenia, Greece, Denmark, Ireland, Finland, Estonia, Spain, Slovakia, Netherlands, Poland, Norway, Italy, Portugal, Belgium, Germany, Romania, Bulgaria
28/10/2025
Phase III
BioNTech SE
Female Urogenital Diseases and Pregnancy Complications
Denmark, Poland, Italy, Finland, Czechia, Sweden, Greece, Belgium, Norway, Hungary, Germany, Austria, France, Spain, Netherlands
27/10/2025
Phase III
Biodexa Limited, Rapamycin Holdings Inc.
Virus Diseases
Denmark, Spain, Germany, Netherlands, Italy
27/10/2025
Phase I
Xencor Inc.
Neoplasms
Spain, France, Belgium, Denmark
27/10/2025
Phase III
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Greece, Czechia, France, Sweden, Romania, Belgium, Austria, Bulgaria, Italy, Netherlands, Denmark, Germany, Poland, Hungary, Spain, Norway
24/10/2025
Phase III
Eidos Therapeutics Inc.
Cardiovascular Diseases
Germany, Portugal, Netherlands, France, Spain, Italy, Ireland, Belgium, Sweden, Denmark, Greece
22/10/2025
Rows per page Showing 1–311 of 311
1
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 21 November 2026. https://priyalifescience.com/clinical-trials-europe/country/denmark

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,905 trial records at the last sync on 21 Nov 2026, 03:17 UTC; this register shows the 2,554 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

This page shows the 311 of those trials with a site in Denmark.

How many recently authorised EU trials have a site in Denmark?

311 of the 2,554 most recently authorised trials in this register list a site in Denmark; 145 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

Summary by phase

Trials by phase (Denmark), 311 trials
PhaseTrialsShare
Phase III14546.6%
Phase II7423.8%
Phase I3410.9%
Phase IV3310.6%
Phase I/II258%

Most active sponsors

Lead sponsors with the most trials (Denmark)
Lead sponsorTrials
Region Hovedstaden24
AstraZeneca AB16
F. Hoffmann-La Roche AG14
Novo Nordisk A/S14
Region Midtjylland14
Merck Sharp & Dohme LLC12
Novartis Pharma AG10
Odense University Hospital9
Bristol-Myers Squibb Services Unlimited Company8
Rigshospitalet8
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.